Walvax BioTech (300142) — Net Asset Quality Index
Walvax BioTech (300142) has a Net Asset Quality Index of 70.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥11.13 Billion minus total liabilities of CN¥3.31 Billion yields net assets of CN¥7.81 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Walvax BioTech (300142) asset resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Walvax BioTech Net Asset Quality Index Over Time (2007–2025)
This chart shows how Walvax BioTech's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 70.2%, representing net assets of CN¥7.81 Billion against total assets of CN¥11.13 Billion CNY. See 300142 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Walvax BioTech (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Walvax BioTech from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Walvax BioTech.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 81.3% | CN¥9.81 Billion | CN¥12.07 Billion | CN¥2.26 Billion | ▲ +3.1 pp |
| 2024 | 78.2% | CN¥11.51 Billion | CN¥14.72 Billion | CN¥3.22 Billion | ▲ +5.1 pp |
| 2023 | 73.1% | CN¥11.40 Billion | CN¥15.59 Billion | CN¥4.19 Billion | ▲ +1.4 pp |
| 2022 | 71.7% | CN¥10.99 Billion | CN¥15.34 Billion | CN¥4.35 Billion | ▼ -1.5 pp |
| 2021 | 73.1% | CN¥10.00 Billion | CN¥13.67 Billion | CN¥3.68 Billion | ▼ -8.2 pp |
| 2020 | 81.3% | CN¥7.85 Billion | CN¥9.65 Billion | CN¥1.80 Billion | ▲ +0.6 pp |
| 2019 | 80.7% | CN¥5.67 Billion | CN¥7.02 Billion | CN¥1.35 Billion | ▲ +8.1 pp |
| 2018 | 72.6% | CN¥5.26 Billion | CN¥7.24 Billion | CN¥1.98 Billion | ▲ +12.1 pp |
| 2017 | 60.5% | CN¥3.56 Billion | CN¥5.88 Billion | CN¥2.32 Billion | ▲ +4.8 pp |
| 2016 | 55.7% | CN¥3.52 Billion | CN¥6.32 Billion | CN¥2.80 Billion | ▲ +7.4 pp |
| 2015 | 48.3% | CN¥3.02 Billion | CN¥6.26 Billion | CN¥3.23 Billion | ▼ -5.5 pp |
| 2014 | 53.8% | CN¥3.21 Billion | CN¥5.97 Billion | CN¥2.76 Billion | ▲ +5.9 pp |
| 2013 | 47.9% | CN¥2.94 Billion | CN¥6.14 Billion | CN¥3.20 Billion | ▼ -23.3 pp |
| 2012 | 71.2% | CN¥3.17 Billion | CN¥4.45 Billion | CN¥1.28 Billion | ▼ -19.0 pp |
| 2011 | 90.2% | CN¥2.71 Billion | CN¥3.01 Billion | CN¥293.62 Million | ▲ +4.8 pp |
| 2010 | 85.4% | CN¥2.55 Billion | CN¥2.99 Billion | CN¥435.52 Million | ▲ +40.2 pp |
| 2009 | 45.2% | CN¥174.69 Million | CN¥386.12 Million | CN¥211.43 Million | ▲ +12.7 pp |
| 2008 | 32.6% | CN¥98.36 Million | CN¥301.90 Million | CN¥203.54 Million | ▲ +24.5 pp |
| 2007 | 8.1% | CN¥17.66 Million | CN¥217.52 Million | CN¥199.86 Million | — |